摘要
目的探讨联合检测SATB2、CK20及CK7在结直肠癌中的诊断价值。方法应用免疫组织化学法检测210例结直肠癌组织、100例非结直肠癌癌组织、90例肠癌淋巴结转移灶及50例正常结直肠黏膜中SATB2、CK20及CK7蛋白的表达情况。结果CK20＋／CK7-联合检测诊断结直肠癌的灵敏度为78．1％，特异度为92．0％；CK20＋／SATB2＋／CK7-联合检测灵敏度为57．1％，特异度为98．0％；CK20＋／CK7-或SATB2＋／CK7-联合检测，灵敏度为85．7％，特异度为90．0％。结论联合检测CK20＋／CK7-／SATB2＋可提高结直肠癌诊断的特异度。在结直肠癌的诊断中，SATB2可作为一个重要的免疫组织化学补充检测指标。
Objective To study the diagnostic value of SATB2, together with CK7 and CK20, in colorectal cancer. Methods Immunohistochemical study for SATB2, CK7 and CK20 was carried out in 210 cases of colorectal cancer tissue, 100 cases of non-colorectal cancer tissue, 90 cases of lymph node metastases and 50 cases of normal colorectal mucosa. Results The sensitivity and specificity of CK20 ＋/ CK7 - immunophenotype for diagnosis of colorectal adenocarcinoma were 78. 1% and 92. 0% , respectively. When triple markers were used, the immunophenotype CK20 ＋/CK7 -/SATB2 ＋ had a sensitivity of 57. 1% and a specificity of 98.0%. When combining the immunophenotype of SATB2 ＋/CK7 - or CK20 ＋/CK7-, the sensitivity was 85.7% and specificity was 90.0%. Conclusions A panel of immunohistochemical markers SATB2, CK7 and CK20 could increase the specificity for diagnosis of colorectal adenocarcinoma significantly. SATB2 is considered as a useful adjunct in this respect.
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2015年第8期578-581,共4页
Chinese Journal of Pathology
基金
国家自然科学基金（81171391）
苏州市科教兴卫青年科技项目（KJXW2013023）
